Now you can generate 100 times the data in 10% of the time, using just 1% of the sample required by older platforms.
By screening and characterizing antibodies at the same time, HT-SPR can help researchers identify the best drug candidates from a vast library of antibodies in just hours or days. Deducing which epitope each antibody binds, how strongly it binds, and its mechanism of action make the new techniques mandatory for any lab that wants to keep pace.
“The LSA gives researchers a tremendous amount of data to make the right decisions about which leads to advance,” says Dr. Margaret Wong, Senior Director at LakePharma. “Since the installment of the first instrument in 2018, we have doubled our LSA footprint as demand from our clients for these kinds of data has been exponential. We cannot imagine discovery and engineering without it.”